Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

Trial Details

NCT ID
NCT05088226
Phase
PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Ruxolitinib combined with Chidamide.
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
  • Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
  • All patients should aged 12 to 65 years;
  • Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →